Press coverage about Psychemedics (NASDAQ:PMD) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Psychemedics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.9662083972572 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
PMD traded down $0.32 during trading on Friday, reaching $20.12. 1,946 shares of the stock traded hands, compared to its average volume of 14,573. Psychemedics has a fifty-two week low of $15.99 and a fifty-two week high of $27.99. The stock has a market cap of $108.80, a price-to-earnings ratio of 22.01 and a beta of 0.73. The company has a current ratio of 3.28, a quick ratio of 3.28 and a debt-to-equity ratio of 0.13.
Psychemedics (NASDAQ:PMD) last announced its quarterly earnings results on Wednesday, March 7th. The company reported $0.22 earnings per share for the quarter. Psychemedics had a return on equity of 29.23% and a net margin of 15.42%. The company had revenue of $9.76 million during the quarter.
Psychemedics Company Profile
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.